<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7914428</article-id><article-id pub-id-type="pmc">2033505</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sulkes</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smyth</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sessa</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dirix</surname><given-names>L. Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vermorken</surname><given-names>J. B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kaye</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wanders</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Franklin</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>LeBail</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Verweij</surname><given-names>J.</given-names></name></contrib></contrib-group><aff>Institute of Oncology, Beilinson Medical Center, Petah Tiqva, Israel.</aff><pub-date pub-type="ppub"><month>8</month><year>1994</year></pub-date><volume>70</volume><issue>2</issue><fpage>380</fpage><lpage>383</lpage><abstract><p>Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v. over 60 min without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patients and retroperitoneal lymph nodes in 16. Eight of the 33 evaluable patients (24%) achieved a partial remission for a median of 7.5 months (3-11+). An additional 11 patients had stabilisation of disease. The patients received a median of four cycles of docetaxel (range 1-8) for a total of 156 courses. Dose reduction was necessary in 30 cycles; 14 cycles were delayed a mean of 3 days. Haematological toxicity consisted mainly of non-cumulative neutropenia, with a median nadir count of 0.35 x 10(9) l-1 (0.04-1.64) and eight episodes (5%) of leucopenic fever; non-haematological toxicities included alopecia, mild nausea and vomiting and allergic manifestations such as skin rash and pruritus. There were no drug-related deaths. Our data indicate that docetaxel is an active agent in advanced gastric cancer; further clinical investigations seem warranted.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00054-0200.tif" xlink:title="scanned-page" xlink:role="380" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00054-0201.tif" xlink:title="scanned-page" xlink:role="381" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00054-0202.tif" xlink:title="scanned-page" xlink:role="382" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00054-0203.tif" xlink:title="scanned-page" xlink:role="383" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

